MedTrace Logo

To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)

NCT04541485 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-09-23

No results posted yet for this study

Summary

This study is designed to assess the safety and tolerability of single doses of DWRX2003 in COVID-19 patients.

Conditions

  • COVID-19 Patients

Interventions

DRUG

DWRX2003

Intramuscularly injection at pre-defined injection sites

DRUG

Placebo

Intramuscularly injection at pre-defined injection sites

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-04
Primary Completion
2021-03-03
Completion
2021-03-23

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04541485 on ClinicalTrials.gov